Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast

Co-Diagnostics (CODX) will release its third quarter 2026 financial results after the market close on November 12, 2026.

Rhea-AI Impact

(High)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Co-Diagnostics (CODX) will release its third quarter 2026 financial results after the market close on November 12, 2026. A conference call and webcast will follow at 4:30 p.m. ET, featuring CEO Dwight Egan and Executive Vice President of Finance and Accounting Daniel Bohrer. A recording will later be available on the company's website.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/29/2026 - 09:15 AM EDT

SALT LAKE CITY, Oct. 29, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its third quarter 2026 financial results on Thursday, November 12, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer and Daniel Bohrer, Executive Vice President of Finance and Accounting.

The conference call and webcast will be available via:

Webcast: ir.co-dx.com on the Events & Webcasts page, or accessible directly here

Conference Call: 1-888-880-3330 (Toll Free) or 1-646-357-8766 (Toll)

If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-announces-third-quarter-2026-earnings-release-date-and-webcast-302923340.html